4 active not recruiting, 1 completed, 1 recruiting. 3 Phase 2, 2 Phase 1, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Not applicable | 1 | Active not recruiting 1 |
| Phase 4 | 1 | Active not recruiting 1 |
Follow Diffuse Astrocytoma: new trials by email Literature Review of Diffuse Astrocytoma trials Research Report on Diffuse Astrocytoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas Biospecimen Collection, Eflornithine, Lumbar Puncture - Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 33 | 2026-06-23 | 2026-06-24 |
| Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms ONC206 - Central Nervous System Neoplasms, Glioblastoma | Phase 1 | Active not recruiting | Jazz Pharmaceuticals | 35 | 2020-10-26 | 2026-11-09 |
| Pediatric Long-Term Follow-up and Rollover Study dabrafenib, trametinib - Diffuse Astrocytoma, Anaplastic Astrocytoma | Phase 4 | Active not recruiting | Novartis Pharmaceuticals | 163 | 2019-11-04 | 2026-08-27 |
| Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma Hippocampal-avoidance proton therapy - Glioma, Pilocytic Astrocytoma | Not applicable | Active not recruiting | St. Jude Children's Research Hospital | 48 | 2019-08-28 | 2026-09-15 |
| Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma Biospecimen Collection, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis - Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma | Phase 2 | Active not recruiting | NRG Oncology | 120 | 2018-01-23 | 2026-07-28 |
| Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors Dabrafenib, trametinib, Carboplatin - Diffuse Astrocytoma, Anaplastic Astrocytoma | Phase 2 | Completed | Novartis Pharmaceuticals | 151 | 2017-12-28 | 2023-12-13 |
Astrocytoma (6) · Glioma (6) · Oligodendroglioma (5) · Glioblastoma (4) · Ganglioglioma (3) · Ganglioneuroma (2) · Neurocytoma (2) · Central Nervous System Neoplasms (1) · Choroid Plexus Neoplasms (1) · Ependymoma (1) · Gliosarcoma (1) · Histiocytosis, Langerhans-Cell (1) · Lymphoma, Follicular (1) · Medulloblastoma (1) · Meningioma (1)
Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Germ Cell and Embryonal (6) · Neoplasms, Glandular and Epithelial (6) · Neoplasms, Nerve Tissue (6) · Neoplasms, Neuroepithelial (5) · Neuroectodermal Tumors (5) · Brain Diseases (3) · Brain Neoplasms (3) · Central Nervous System Diseases (3) · Neoplasms by Site (3) · Nervous System Diseases (3) · Nervous System Neoplasms (3) · Central Nervous System Neoplasms (2) · Hemic and Lymphatic Diseases (2)
Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · dabrafenib (2) · trametinib (2) · Carboplatin (1) · Eflornithine (1) · ONC206 (1) · Proton Therapy (1) · Protons (1) · Radiotherapy, Intensity-Modulated (1) · Spinal Puncture (1) · Temozolomide (1) · Transurethral Resection of Bladder (1) · Vincristine (1)
Novartis Pharmaceuticals (2) · Jazz Pharmaceuticals (1) · Mayo Clinic (1) · NRG Oncology (1) · St. Jude Children's Research Hospital (1)
United States (6) · Argentina (2) · Australia (2) · Belgium (2) · Brazil (2) · Canada (2) · Czechia (2) · Denmark (2) · Finland (2) · France (2) · Germany (2) · Israel (2) · Italy (2) · Japan (2) · Netherlands (2)
David R Grosshans (1) · Terence C. Burns, MD, PhD (1) · Thomas Merchant, MD (1)
PMID 34331515, PMID 35417530, PMID 37610803, PMID 37643378, PMID 37733309, PMID 41740060
2015 (1), 2023 (1), U10CA180868 (1)